Research shows impaired humoral immunity and altered immune responses in IBD patients receiving anti-TNF biologics after mRNA vaccination, indicating a need for careful immunization strategies.
Description The impact of anti-cytokine therapies on vaccine-induced immunity is incompletely understood. The IMmune resPonse After Covid-19 vaccination during maintenance Therapy (IMPACT) study investigated the immunogenicity of the SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease (IBD), treated with anti-TNF or anti-IL-12/23. Blood was collected pre and post 1-4 doses of BNT162b2 or mRNA-1273 vaccines. IBD patients showed greater waning of cellular and humoral immunity by 3 months post dose 2 compared to healthy controls (HC). Booster doses prolonged responses, albeit anti-TNF treated IBD patients showed reduced antibody titers across 4 vaccine doses. Spike (S)-specific memory B cells (MBCs) from HC, anti-TNF and anti-IL-12/23 treated IBD patients revealed predominant extrafollicular responses in anti-TNF treated patients, as indicated by higher proportions of marginal zone-like B cells and atypical MBCs, and lower proportions of classical MBCs. Anti-TNF treated patients also had lower plasma IgG:IgM ratios. MBCs from anti-TNF patients had less somatic hypermutation and their plasma IgG responses were of lower avidity. Thus, anti-TNF biologics impair humoral immunity to SARS-CoV-2 as revealed by low S-specific Ig titers, decreased affinity maturation, and extrafollicular-skewed memory responses, consistent with the inhibition of germinal center responses by TNF blockade. In contrast, treatment with anti-IL-12/23 had minimal impact on humoral immunity to vaccination. Funding Sources Supported by the Canadian Graduate Scholarship Doctoral Award (MWC), Canadian Institutes of Health research grants VR-1 172 711, GA2-177716 (to THW and ACG) and by a donation from Juan and Stefania Speck. THW holds the Canada Research Chair in Anti-viral Immunity at the University of Toronto; ACG is the Canada Research Chair in Functional Proteomics. Topic Categories Immune Mechanisms of Human Disease (HUM)
No takes yet. Share an insight, caveat, or question.
Cheung et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: